Skip to main content
TrialFinder
ResourcesAbout
Privacy policyTerms of useAccessibilityFAQFeedback
Support the project (opens in a new tab)

We use functional cookies to improve your experience. See our Privacy policy.

Trial data comes from ClinicalTrials.gov (US) and is shown for information only.

TrialFinder is not medical advice. Always talk with your doctor before deciding on a trial.

In memory of Dov Korn ❤️

Colorectal Cancer Clinical Trials: MSI, KRAS, BRAF | TrialFinder
HomeResourcesColorectal (Colon) Cancer Clinical Trials: Colon vs Rectal, MSI Status, and Prior Treatment

Back to Resources

Published · October 3, 2026· Updated October 8, 2026

Colorectal (Colon) Cancer Clinical Trials: Colon vs Rectal, MSI Status, and Prior Treatment

Colorectal cancer starts in the colon or the rectum. Doctors often group the two because the cells look similar under the microscope, but the treatment plan is not always the same. "Colon cancer" on a report and "rectal cancer" on a report can lead to different trials, so the exact location matters from the first search.

Stage and the goal of treatment matter just as much. A study for cancer that was found early and may be removed with surgery is a different study from one for cancer that has spread to the liver, lungs, or elsewhere (metastatic disease). Previous treatment also changes which studies may fit: the drugs already used, how the cancer responded, and whether surgery has been done.

The tumor itself is also tested. Results such as MSI/dMMR, KRAS, NRAS, BRAF, and HER2 can decide which treatments make sense and which trials a person can join. A positive result alone does not establish eligibility, and not every test applies to every stage.

Colorectal cancer trials study new drugs, new combinations, the order in which treatments are given, and ways to decide who needs more treatment after surgery. A clinical trial is one option to raise with the treating oncologist. It is not automatically better than approved treatment. The useful question is whether a study matches the exact location, stage, test results, and treatment history.

Colon and rectal cancer are not always searched the same way

Colon cancer is often treated with surgery first when the disease is limited to the bowel and nearby lymph nodes. After surgery, some people are offered chemotherapy to lower the chance that the cancer returns. Trials in this setting are called adjuvant trials, and they may look at which treatment to give or who needs it.

Rectal cancer sits in a tight space in the pelvis, and the plan often starts before surgery, with chemotherapy, radiation, or both. Some approaches give all of the chemotherapy and radiation first (sometimes called total neoadjuvant therapy), and some people may be offered a way to avoid surgery if the tumor responds fully. Rectal studies often have their own protocol and eligibility rules, so a study listed for colon cancer should not be assumed to accept rectal cancer, and the other way around.

When the cancer has spread, most trials are built around metastatic disease. They may ask whether the cancer can be removed or treated locally, which drug combination to use first, or what to try after earlier treatments stop working. A first-line study (for people who have not yet had treatment for metastatic disease) is not the same as a study after one or more earlier lines of treatment.

Previous surgery, chemotherapy, targeted drugs, and immunotherapy can each be required in one study and excluded in another. Discuss the timing of any trial search with the oncologist rather than delaying recommended care while looking.

The plain-language clinical trial glossary can help with terms such as adjuvant, first-line, and standard of care.

Tumor test results that separate one trial from another

The pathology and molecular reports are the starting point. They describe the tumor tissue and, when ordered, the gene changes and proteins in it. Ask for copies, because many trials ask for the actual results.

MSI-high or dMMR (mismatch repair deficient) describes a tumor that cannot repair certain DNA copying errors. It is tested in colorectal cancer because it can point to immunotherapy, and because it can be linked to an inherited condition such as Lynch syndrome. A tumor that is MSS or pMMR (mismatch repair proficient) is a different group, and studies often enroll one group or the other.

KRAS and NRAS (together called RAS) are genes that can carry changes that matter for treatments aimed at the EGFR protein, such as cetuximab and panitumumab. Those drugs are generally not used when a RAS change is present, so a study may require "RAS wild type" or a specific variant. Some KRAS changes, such as KRAS G12C, are the target of newer drugs in their own right, and trials may be built around them.

BRAF V600E is a specific change in the BRAF gene. It is a distinct subgroup with its own treatment studies, and some trials require it while others exclude it.

HER2 is a protein or gene copy-number result that is checked in some metastatic cases. When it is present, certain targeted combinations may be an option, and some studies require it.

Other items on the report can matter too: where the tumor started in the colon, blood tests such as CEA, scan results, and tests after surgery that look for leftover tumor DNA in the blood, which some adjuvant studies use. These are not all biomarkers, but they can affect eligibility. There is no single panel that makes someone eligible for every colorectal cancer trial.

Some treatments mentioned here are already approved in defined settings. Availability depends on the test results, previous treatment, and the country where care is given.

Recruiting colorectal cancer trials

Start with the exact location (colon or rectum), the stage, and the test results, then check the study's criteria for previous treatment. A listing that includes "colorectal cancer" may still accept only one stage, one biomarker group, or people at one point in treatment. Confirm eligibility and local recruitment with the study team.

Open the full TrialFinder search for colorectal cancer.

Questions to ask an oncologist

A short list is usually enough:

  • Is the cancer in the colon or the rectum, and what is the stage? Is the goal of treatment to remove the cancer, lower the chance it returns, or control it long term?
  • Which tumor tests were done: MSI/dMMR, KRAS and NRAS, BRAF, HER2? Can I get a copy of the results? Are any tests still missing?
  • Which treatments have I already had, and how did the cancer respond? Does earlier surgery, chemotherapy, or immunotherapy affect what is open to me?
  • For this stage and these results, what is approved or considered standard where I live? Would looking for a trial delay treatment that should start now?
  • Are there recruiting trials that match this exact profile, and how do their treatment, risks, and visit schedule differ from standard care?

Want to prepare for the appointment? The guide How to Talk to Your Doctor About Clinical Trials explains how to raise the topic and what to bring with you.

Sources

  • NCI: Colorectal cancer
  • NCI PDQ: Colon cancer treatment (patient)
  • NCI PDQ: Rectal cancer treatment (patient)
  • NCI PDQ: Colon cancer treatment (health professional)
  • NCI PDQ: Rectal cancer treatment (health professional)
  • NCI: Cancer staging
  • NCI: Immunotherapy to treat cancer
  • Study eligibility and recruitment information should be checked against the individual record on ClinicalTrials.gov and confirmed with the study team.

FAQ

What is colorectal cancer, in plain language?

Colorectal cancer is cancer that starts in the colon or the rectum. Colon and rectal cancer are often grouped together, but their treatment plans can differ, and so can the trials that fit.

Why does it matter whether the cancer is in the colon or the rectum?

Rectal cancer is often treated with chemotherapy and radiation before surgery, and rectal studies often have their own rules. A colon study may not accept rectal cancer, and the reverse can also be true.

Which tumor tests separate colorectal cancer trials?

MSI/dMMR, KRAS and NRAS, BRAF V600E, and HER2 are the main ones people see on reports. Which of them matters depends on the stage and the protocol. The full report is more useful than a single result.

Do clinical trials replace approved colorectal cancer treatment?

Not automatically. Trials should be compared with the standard options for the exact location, stage, and treatment history. Some targeted drugs and immunotherapies are already approved in certain settings.

What should I ask an oncologist before looking at listings?

Ask for the location, the stage, the tumor test results, and a summary of earlier treatment and response. Then ask whether a study fits and whether the search can happen without delaying needed care.

Further reading

Start Here: How to Search for Clinical Trials on TrialFinder A step-by-step guide to finding clinical trials on TrialFinder. Learn how to search by condition, use filters, and understand your results.

Before You Join a Clinical Trial: Screening, Informed Consent, and Red Flags Learn what screening and informed consent involve before you join a clinical trial, which questions to ask, and which red flags mean you should walk away.

Not a Perfect Match? Tips for Getting Into a Clinical Trial Anyway A rejection from a clinical trial doesn't have to be the end. Practical tips for patients and caregivers who hit a wall.

How to Talk About Clinical Trials with a Family Member A guide for caregivers on introducing clinical trials to a loved one who is hesitant, tired, or afraid.

ESMO 2026: Four Results You Can Act On Today Four ESMO 2026 results in lung cancer and melanoma with steps you can take now, from biomarker testing to open clinical trials.

Clinical Trials in Mental Health: What Patients and Families Should Know Mental health clinical trials may test medication, therapy, or devices. How they differ from cancer trials, and how to start looking.

The Reminder Moderna and Merck's Personalized mRNA Cancer Vaccine Gives Us About Clinical Trials Moderna and Merck's personalized mRNA vaccine met Phase 3 goals in melanoma. What that shows about joining a clinical trial.

Daraxonrasib (RASONQUE) Is Now FDA-Approved for Metastatic Pancreatic Cancer The FDA approved daraxonrasib (RASONQUE) on August 26, 2026 for metastatic pancreatic cancer after prior therapy.

How to Talk to Your Doctor About Clinical Trials What questions should you ask your doctor about clinical trials? A step-by-step guide for patients: when to bring it up, what to prepare, and what to do after.

What is a Clinical Trial? (It's More Than You Think) How clinical trials work, why they matter, and what patients should know before considering one.

Key Clinical Trial Terms Plain-language explanations of terms patients and families encounter during the clinical trial process.

Share this post
  •  

This article was written by a patient advocate based on personal experience, not by a medical professional. It is not medical advice. Consult your doctor before making any medical decisions.

Looking for a clinical trial?

Search trials

Trial data from ClinicalTrials.gov. For information only.

This list is limited to recruiting studies whose title or listed conditions name colorectal, colon, or rectal cancer. A biomarker or location heading appears only when that term is named in those same fields. Stage and prior treatment are not used as headings, because they are often missing there.

Location

Disease stage

Biomarker

Treatment setting

Loading matching clinical trials

Trials whose title or listed conditions name MSI-high or dMMR

  • Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

    Gastric Cancer · Colon Cancer · MSI-H

    ChinaRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Beijing, China
  • Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer

    Colorectal Cancer · SGLT-2 Inhibitor

    ChinaRecruitingPhase 1
    Simple summary·Eligibility check·Doctor guide
    Chengdu, China

Trials whose title or listed conditions name BRAF

  • Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

    Colorectal Cancer

    2 countriesRecruitingPhase 3
    Simple summary·Eligibility check·Doctor guide
    Hot Springs, United States · Los Angeles, United States
  • Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study

    Colorectal Cancer (CRC)

    ChinaRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Beijing, China
  • Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients

    Colorectal Cancer

    ChinaRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Guangzhou, China
  • Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

    Colorectal Cancer · Liver Metastases

    ChinaRecruitingPhase 2/3
    Simple summary·Eligibility check·Doctor guide
    Guangzhou, China
  • Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

    Colorectal Cancer Metastatic

    ChinaRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Guangzhou, China
  • Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases

    Unresectable Colon Cancer Peritoneal Metastases · PMMR/Ras/BRAF Wild-type

    ChinaRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Huzhou, China

Trials whose title or listed conditions name HER2

  • Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer

    Rectal Cancer · HER2-positive

    ChinaRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Beijing, China

Trials whose title or listed conditions name rectal cancer

  • Explained in plain language

    SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak

    Rectal Cancer

    ChinaRecruitingPhase 4
    Simple summary·Eligibility check·Doctor guide
    Beijing, China
  • Single Versus Double Stapling and Two Purse-String Techniques in Rectal Cancer Surgery

    Rectal Cancer

    EgyptRecruiting
    Simple summary·Eligibility check·Doctor guide
    Alexandria, Egypt
  • Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy

    Rectal Adenocarcinoma

    United StatesRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Houston, United States
  • Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001

    Rectal Cancer

    United StatesRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Lexington, United States · Omaha, United States
  • Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial

    Rectal Cancers

    ChinaRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Guangzhou, China
  • Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)

    Rectal Cancer · Colon Cancer · Ovarian Cancer

    FranceRecruiting
    Simple summary·Eligibility check·Doctor guide
    Montpellier, France
  • Evaluation of Gynecological and Sexual Sequelae

    Rectal Cancer Patients

    FranceRecruiting
    Simple summary·Eligibility check·Doctor guide
    Rouen, France
  • Quality Of Life In Colorectal Cancer Survivors

    Colorectal Cancer · Colon Cancer · Rectal Cancer

    SloveniaRecruiting
    Simple summary·Eligibility check·Doctor guide
    Ljubljana, Slovenia
  • A Randomised Clinical Investigation to Assess Efficacy of Low Volume Transanal Irrigation by Qufora® IrriSedo MiniGo Versus Conservative Treatment for Low Anterior Resection Syndrome Patients

    Gastroenterology · LARS - Low Anterior Resection Syndrome · Rectal Cancer

    FranceRecruiting
    Simple summary·Eligibility check·Doctor guide
    Amiens, France · Besançon, France
  • Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.

    Locally Advanced Rectal Cancer

    ChinaRecruiting
    Simple summary·Eligibility check·Doctor guide
    Beijing, China
  • Proximally Extended Resection for Rectal Cancer After Neoadjuvant Chemoradiotherapy

    Rectal Cancer

    ChinaRecruiting
    Simple summary·Eligibility check·Doctor guide
    Guangzhou, China

Open the full TrialFinder search for Colorectal cancer